NDC 50090-6838 – Lisinopril and Hydrochlorothiazide
Lisinopril 10 mg/1; Hydrochlorothiazide 12.5 mg/1 · Tablet · Oral
Product NDC50090-6838
Product details
- Brand name
- Lisinopril and Hydrochlorothiazide
- Generic name
- Lisinopril and Hydrochlorothiazide Tablets
- Labeler
- A-S Medication Solutions
- Dosage form
- Tablet
- Route
- Oral
- Marketing category
- ANDA · ANDA076230
- Marketed since
- March 12, 2015
- Listing expires
- December 31, 2026
- Pharmacologic class
- Angiotensin Converting Enzyme Inhibitor; Thiazide Diuretic
Active ingredients
- Lisinopril 10 mg/1
- Hydrochlorothiazide 12.5 mg/1
Uses, dosage, side effects and warnings for Lisinopril and Hydrochlorothiazide →
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 50090-6838-0 | 90 TABLET in 1 BOTTLE (50090-6838-0) | Nov 27, 2023 |
Other Lisinopril and Hydrochlorothiazide products
- 50090-6752 Lisinopril 20 mg/1; Hydrochlorothiazide 12.5 mg/1 · Tablet · A-S Medication Solutions
- 50090-6204 Lisinopril 20 mg/1; Hydrochlorothiazide 12.5 mg/1 · Tablet · A-S Medication Solutions
- 50090-7751 Hydrochlorothiazide 12.5 mg/1; Lisinopril 10 mg/1 · Tablet · A-S Medication Solutions
- 50090-7294 Lisinopril 20 mg/1; Hydrochlorothiazide 25 mg/1 · Tablet · A-S Medication Solutions
- 50090-6976 Hydrochlorothiazide 25 mg/1; Lisinopril 20 mg/1 · Tablet · A-S Medication Solutions
- 50090-6094 Lisinopril 10 mg/1; Hydrochlorothiazide 12.5 mg/1 · Tablet · A-S Medication Solutions
- 50090-6062 Lisinopril 10 mg/1; Hydrochlorothiazide 12.5 mg/1 · Tablet · A-S Medication Solutions
- 50090-6034 Lisinopril 20 mg/1; Hydrochlorothiazide 25 mg/1 · Tablet · A-S Medication Solutions
- 50090-2565 Hydrochlorothiazide 12.5 mg/1; Lisinopril 10 mg/1 · Tablet · A-S Medication Solutions
- 50090-2974 Hydrochlorothiazide 25 mg/1; Lisinopril 20 mg/1 · Tablet · A-S Medication Solutions
- 0591-0861 Lisinopril 20 mg/1; Hydrochlorothiazide 12.5 mg/1 · Tablet · Actavis Pharma, Inc.
- 0591-0862 Lisinopril 20 mg/1; Hydrochlorothiazide 25 mg/1 · Tablet · Actavis Pharma, Inc.